NCT03272217 - Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 13, 2017

Primary Completion Date

May 27, 2021

Study Completion Date

March 17, 2022

Conditions

Urothelial Carcinoma

Interventions

DRUG

Atezolizumab

Atezolizumab 1200 mg (flat dose) IV every 21 days

DRUG

Bevacizumab

Bevacizumab 15 mg/kg IV every 21 days

Trial Locations (8)

New York University Clinical Cancer Center, New York

Memorial Sloan Kettering Cancer Center, New York

West Cancer Center University of Tennessee, Memphis

Cleveland Clinic, Cleveland

Froedtert & The Medical College of Wisconsin, Milwaukee

HealthPartners Institute, Minneapolis

Rush University Medical Center, Chicago

University of Arizona at Dignity Health St. Joseph, Phoenix